Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Micromedic Technologies

Experimental Drug Protects Animal Model from Measles-Like Virus

By BiotechDaily International staff writers
Posted on 04 May 2014
Print article
Image: Ultrastructural appearance of a single measles virus particle as revealed by thin-section transmission electron microscopy (TEM). It is 100–200 nm in diameter, with a core of single-stranded RNA, and is closely related to the rinderpest and canine distemper viruses (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Image: Ultrastructural appearance of a single measles virus particle as revealed by thin-section transmission electron microscopy (TEM). It is 100–200 nm in diameter, with a core of single-stranded RNA, and is closely related to the rinderpest and canine distemper viruses (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Working with an animal model that mimics measles in humans, a team of molecular virologists have verified that a novel antiviral drug may complement the currently used vaccine and lead to eradication of the disease.

To better study the measles virus under laboratory conditions investigators at Georgia State University (Atlanta, USA) and colleagues at Emory University (Atlanta, GA, USA) and the Paul-Ehrlich Institute (Langen, Germany) used zoonotic Canine distemper virus (CDV), which induces a disease in ferrets with 100% lethality.

The investigators used the ferret model to evaluate the experimental drug ERDRP-0519, which targets the viral RNA polymerase. This enzyme is required for replication of the virus, as it catalyzes the synthesis of a complementary strand of RNA from the original viral RNA template.

Results reported in the April 16, 2014, issue of the journal Science Translational Medicine revealed that prophylactic oral drug treatment of the ferrets protected them from a lethal dose of CDV administered intranasally. Ferrets that received the drug after having been infected with the same dose of virus showed low-grade viral loads, remained asymptomatic, and recovered from infection, whereas control animals succumbed to the disease. Animals that had recovered from CDV infection demonstrated a robust immune response and were protected against re-challenge with a lethal CDV dose.

The investigators stated that the drug is not intended as a substitute for vaccination, but as an additional weapon in a concerted effort to eliminate the disease. "The emergence of strong antiviral immunity in treated animals is particularly encouraging, since it suggests that the drug may not only save an infected individual from disease but contribute to closing measles immunity gaps in a population," said senior author Dr. Richard Plemper, professor in the center for inflammation, immunity, and infection at Georgia State University.

Related Links:

Georgia State University
Emory University
Paul-Ehrlich Institute



Print article

Channels

Genomics/Proteomics

view channel
Image: Molecular model of E3 ubiquitin ligase (green), E2 ubiquitin enzyme (orange), \"activated ubiquitin\" (cyan), and \"allosteric ubiquitin\" (blue) (Photo courtesy of Dr. Bernhard Lechtenberg, Sanford Burnham Prebys Medical Discovery Institute).

Researchers Resolve Molecular Structure of Critical Ubiquitin-Binding Enzyme

The molecular structure of a protein complex critically involved in diverse cellular functions such as cell signaling, DNA repair, and mounting anti-inflammatory and immune responses has been elucidated... Read more

Business

view channel

Purchase Agreement to Boost Ebola Vaccine Development

A deal to help boost development of a vaccine to protect against Ebolavirus infection was finalized at the recent Davos Conference in Switzerland. Gavi (Geneva, Switzerland), the global alliance for vaccines and immunizations, announced that it would spend five million USD to purchase the Ebola vaccine under development... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.